8.4 Thyroid & Lipid Disorders

8.4 Thyroid & Lipid Disorders

Quick Answer: Levothyroxine replaces thyroid hormone—take on an empty stomach, separate from iron and calcium, and monitor TSH. Carbimazole treats hyperthyroidism with infection/agranulocytosis red flags. For lipids, use statin intensity concepts, assess muscle symptoms, check LFTs when indicated, add ezetimibe for further LDL lowering, and reserve fibrates mainly for triglyceride-focused scenarios. Look for secondary causes of dyslipidaemia.

Thyroid and lipid therapeutics reward careful counselling and monitoring (Standards 3.2 and 3.3) more than memorising every microgram tablet strength.

Hypothyroidism — levothyroxine counselling

Levothyroxine is synthetic T4, titrated to clinical response and thyroid function tests—primarily TSH in primary hypothyroidism (free T4 supports interpretation).

How to take it

• Take once daily on an empty stomach, typically 30–60 minutes before breakfast, or consistently at bedtime hours after the last meal—consistency of timing matters as much as the clock choice.
• Swallow with water; avoid taking simultaneously with coffee in a way that the patient has not stabilised (be consistent).
• Do not switch brands casually without monitoring if the patient is finely titrated—bioequivalence issues can matter clinically for some people; document brand and recheck TSH after product changes when clinically relevant.

Binding and absorption interactions

Separate levothyroxine from agents that reduce absorption:

Enzyme inducers (e.g. some anticonvulsants, rifampicin) and increased binding needs in pregnancy change dose requirements—pregnancy needs prompt endocrine/GP review and more frequent TFT monitoring.

Monitoring TSH

• Recheck TSH after dose changes (often around 6–8 weeks because of long half-life), then less often when stable.
• Symptoms of under-replacement: fatigue, weight gain, cold intolerance, constipation, bradycardia.
• Over-replacement risks: palpitations, AF, osteoporosis risk with chronic excess, anxiety, heat intolerance.
• Do not adjust dose every few days based on transient symptoms alone.

Adherence is a common cause of “resistant” abnormal TSH—ask non-judgementally about missed doses and timing with breakfast coffees and supplements.

Hyperthyroidism — carbimazole concepts

Carbimazole (metabolised to methimazole) reduces thyroid hormone synthesis. Propylthiouracil (PTU) is an alternative in selected situations (e.g. certain pregnancy trimesters/preferences—specialist domain).

Intern counselling and safety:

• Regular TFT monitoring guides dose down-titration.
• Agranulocytosis (rare): warn patients to stop and seek urgent medical care if they develop fever, sore throat, mouth ulcers, or other infection signs—do not wait for the next routine appointment.
• Rash and GI upset can occur; severe liver injury is a concern especially discussed with PTU.
• Beta-blockers (e.g. propranolol) may be used symptomatically for tremor/tachycardia under medical direction while awaiting euthyroidism.
• Radioiodine and surgery are definitive options managed outside community initiation.

Never encourage patients to restart carbimazole after a suspected agranulocytosis episode without specialist clearance.

Lipid disorders — statin intensity concepts

Statins (HMG-CoA reductase inhibitors) are first-line for atherosclerotic risk reduction. Australian practice emphasises intensity and indication (secondary prevention after ACS/IHD, diabetes with risk, high LDL, familial hypercholesterolaemia pathways) rather than treating a mild isolated total cholesterol in isolation.

Counselling: lifelong adherence usually required for risk reduction; take consistently; night dosing traditionally emphasised for short-acting simvastatin, while longer-acting agents are more flexible—follow product directions.

Muscle symptoms

Myalgia is common in the community; true myopathy and rhabdomyolysis are uncommon but serious.

Approach:

1. Characterise pain (diffuse? proximal? strength loss? dark urine?).
2. Review interacting drugs that raise statin levels (e.g. strong CYP3A4 inhibitors with simvastatin/atorvastatin—macrolides, azoles, certain calcium channel blockers, grapefruit in excess).
3. Check for hypothyroidism, strenuous new exercise, or vitamin D issues as contributors when relevant.
4. Escalate for CK testing when clinically indicated (severe symptoms, weakness, dark urine).
5. Do not tell every patient with mild aches to stop secondary-prevention statin permanently without a plan—rechallenge, dose reduction, alternate statin, or non-statin strategies exist.

LFTs when indicated

Baseline liver enzymes are often checked before statin start. Routine frequent LFT monitoring in asymptomatic patients is less emphasised than previously; recheck when symptoms suggest hepatotoxicity (jaundice, dark urine, severe fatigue/abdominal pain) or as per protocol. Statins are not automatically forbidden in stable mild LFT abnormalities—clinical judgement applies—but decompensated liver disease needs specialist input.

Ezetimibe add-on

Ezetimibe inhibits intestinal cholesterol absorption and is commonly added when LDL-C remains above target on maximally tolerated statin, or when statin intensity is limited by intolerance. Generally well tolerated (GI effects uncommon). Counsel that it is additive to statin therapy for LDL lowering, not a lifestyle-free cure.

Fibrates and triglycerides

Fibrates (e.g. fenofibrate, gemfibrozil) primarily lower triglycerides and raise HDL modestly. Use cases focus on marked hypertriglyceridaemia (pancreatitis risk) or selected residual risk scenarios.

Safety:

• Combination of gemfibrozil + statin has higher myopathy risk—generally avoided; fenofibrate + statin is managed more cautiously but still needs awareness.
• Renal dosing considerations; gallstone risk; monitor as per AMH.

Severe hypertriglyceridaemia also needs alcohol review, glycaemic control, and secondary cause work-up—not fibrate initiation in isolation without context.

Secondary causes of dyslipidaemia (brief but examinable)

Before attributing all lipid results to primary diet/genetics alone, consider:

• Hypothyroidism
• Diabetes / poor glycaemic control
• Nephrotic syndrome / chronic kidney disease
• Cholestasis / liver disease
• Alcohol excess
• Medicines: some atypical antipsychotics, corticosteroids, thiazides/beta-blockers (variable effects), isotretinoin, immunosuppressants, etc.
• Pregnancy (physiologic changes—specialist interpretation)

Correcting the secondary driver can improve the lipid profile and prevent futile polypharmacy.

Integrating thyroid and lipids

Hypothyroidism can raise cholesterol; starting levothyroxine may improve lipids secondary to restored thyroid status. Conversely, over-replacement is not a lipid strategy. Always read the whole patient: a new high TSH plus high LDL may need thyroid treatment and later lipid reassessment, not automatic maximal statin panic alone.

Exam mindset

High-yield vignettes: levothyroxine with ferrous sulfate timing; TSH recheck interval concept; carbimazole and sore throat/fever; high-intensity statin after MI; simvastatin interaction with a macrolide; when to worry about muscle pain and dark urine; ezetimibe add-on purpose; fibrate for triglycerides; and hypothyroidism as a secondary cause of dyslipidaemia. Choose answers that protect absorption consistency, toxicity red flags, and indication-driven lipid intensity.